Novartis Wins EU Thumbs Up for MS Treatment
Kesimpta could become the first and only self-administered, targeted B-cell therapy for patients in Europe with relapsing forms of multiple sclerosis.
You may also be interested in...
Fewer patients with multiple sclerosis are switching treatment during the pandemic but despite that, and the arrival of competition from Novartis's Kesimpta, Roche insists Ocrevus growth remains strong.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
New products from Paion, Arvelle, Incyte and many others have been recommended for approval by the European Medicines Agency. Meanwhile, the agency has explained why the EU marketing authorization application for Dexamethasone Taw, for treating COVID-19 patients, was withdrawn.